1. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study 
Dean J. Kereiakes, MD, FACC, FSCAI, Jennifer G. Robinson, MD, MPH, Christopher P. Cannon, MD, Christelle Lorenzato, MSc, Robert Pordy, MD, Umesh Chaudhari, MD, Helen M. Colhoun, MD, MFPHM, FRCP(Ed) 
American Heart Journal 
Volume 169, Issue 6, Pages e13 (June 2015)
DOI: /j.ahj
Copyright © 2015 The Authors Terms and Conditions

2. Figure 1 Patient flow through the study.
Abbreviation: CRF, case report form.
American Heart Journal  , e13DOI: ( /j.ahj )
Copyright © 2015 The Authors Terms and Conditions

3. Figure 2
End point analysis: percent reduction in LDL-C and other lipid parameters from baseline to week 24.
American Heart Journal  , e13DOI: ( /j.ahj )
Copyright © 2015 The Authors Terms and Conditions

4. Figure 3
Achieved calculated LDL-C levels over time with alirocumab and placebo on background maximally tolerated statin with or without other LLT (ITT analysis).
Baselines are described using mean; all other time points are estimated mean (95% CI). Values above and below data points indicate estimated mean percent change from baseline and estimated mean achieved LDL-C levels.
American Heart Journal  , e13DOI: ( /j.ahj )
Copyright © 2015 The Authors Terms and Conditions

5. Figure 4
Low-density lipoprotein cholesterol percent reduction in patients with and without alirocumab dose increase.
American Heart Journal  , e13DOI: ( /j.ahj )
Copyright © 2015 The Authors Terms and Conditions

6. Figure 5
Proportion of patients reaching LDL-C <70 mg/dL (1.81 mmol/L) at week 24.
Multiple imputation method is used to address missing values in the ITT and modified ITT populations. Combined estimate for proportion of patients is obtained by averaging out all the imputed proportions of patients reaching the level of interest.
The P value is statistically significant according to the fixed hierarchical approach used to ensure a strong control of the overall type I error rate at the 0.05 level.
American Heart Journal  , e13DOI: ( /j.ahj )
Copyright © 2015 The Authors Terms and Conditions

7. Figure 6
Differences versus placebo for percent change from baseline in calculated LDL-C at week 24 by demographic characteristics and subgroup analysis (ITT population).
All patients on background of maximally tolerated statin ± other LLT.
Abbreviations: CKD, chronic kidney disease; MI, myocardial infarction. *High-intensity statin: atorvastatin mg or rosuvastatin mg daily.
American Heart Journal  , e13DOI: ( /j.ahj )
Copyright © 2015 The Authors Terms and Conditions

8. Supplementary Figure 1
Distribution of absolute LDL-C levels at baseline and week 24 for (A) all alirocumab-treated patients and (B) all placebo-treated patients (on treatment analyses). C and D, show the distribution within the alirocumab group for (C) alirocumab-treated patients who remained on a dose of 75-mg Q2W through the study and (D) alirocumab-treated patients who received a dose increase to 150-mg Q2W at week 12 if their LDL-C was ≥70 mg/dL at week 8.
American Heart Journal  , e13DOI: ( /j.ahj )
Copyright © 2015 The Authors Terms and Conditions

9. Supplementary Figure 2
Percent reduction in LDL-C from baseline to week 24 by anti-alirocumab antibody status.
American Heart Journal  , e13DOI: ( /j.ahj )
Copyright © 2015 The Authors Terms and Conditions